Rimonabant for treating tobacco dependence

Vascular Health and Risk Management

Volumn 3, Issue 3, 2007, Pages 307-311

  Steinberg, Michael B ^a,b   Foulds, Jonathan ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cessation; Medications; Pharmacotherapy; Rimonabant; Smoking; Tobacco

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CANNABIS; ENDOCANNABINOID; NICOTINE; PLACEBO; RIMONABANT; VARENICLINE;

ABSTINENCE; ANOREXIA; ANXIETY; ARTHRALGIA; BACKACHE; BEHAVIOR THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; FOLLOW UP; GLYCEMIC CONTROL; HEADACHE; HUMAN; INFLUENZA; INSOMNIA; METABOLIC DISORDER; NAUSEA; NONHUMAN; PATHOGENESIS; PREVALENCE; PROGNOSIS; PSYCHOSOCIAL CARE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SMOKING; SMOKING CESSATION; SUSTAINED DRUG RELEASE; TOBACCO DEPENDENCE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

ANIMALS; ENDOCANNABINOIDS; HUMANS; PIPERIDINES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 34547687979     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Anthenelli RM. 2005. Recent advances in the treatment of tobacco dependence. Clinical Neuroscience Research, 5:175-183.
2. Balerio GN, Aso E, Maldonado R. 2006. Role of cannabinoid system in the effects induced by nicotine on anxiety-like behavior in mice. Psychopharmacology, 184:504-13.
3. Blondal T, Gudmundsson LJ, Olafsdottir I, et al. 1999. Nicotine nasal spray with nicotine patch for smoking cessation: a randomized trail with six year follow-up. BMJ, 318:285-9.
4. Bohadana A, Nilsson F, Rasmussen T, et al. 2000. Nicotine Inhaler and Nicotine Patch as a Combination Therapy for Smoking Cessation. Arch Intern Med, 160:3128-34.
5. Cohen C, Perrault G, Griebel G, et al. 2005. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal; reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology, 30:145-55.
6. Dale LC, Anthenelli RM. 2004. Rimonabant as an aid to smoking cessation in smokers motivated to quit: results from a U.S. Multicenter Study-STRATUS U.S. Trial. Abstract presented at the Annual Meeting of the American College of Cardiology.
7. Despres JP, Golay A, Sjostrom L. 2005. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med, 353:2121-34.
8. Fagerstrom K, Balfour DJ. 2006. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin Investig Drugs, 15:107-16.
9. Fiore MC, Bailey WC, Cohen SJ, et al. 2000. Treating Tobacco Use and Dependence: Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service.
10. Gelfand EV, Cannon CP, Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. 2006. J Am Coll Cardiol, 47:1919-26.
11. Gonzales D, Rennard SI, Nides M, et al. 2006. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA, 296:47-55.
12. Henningfield JE, Fant RV, Buchhalter AR, et al. 2005. Pharmacotherapy for nicotine dependence. CA Cancer J Clin, 55:281-99.
13. Hughes JR, Goldstein MG, Hurt RD, et al. 1999. Recent Advances in Pharmacotherapy of Smoking. JAMA, 281:72-76.
14. Hughes J, Stead L, Lancaster T. 2004. Antidepressants for smoking cessation. Cochrane Database Syst Rev, (4), CD000031.
15. Jorenby DE, Leischow SJ, et al. 1999. A Controlled Trial of Sustained- Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation. N Engl J Med, 340:685-691.
16. Jorenby DE, Hays JT, Rigotti NA, et al. 2006. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial JAMA, 296:56-63.
17. Kelley AE. Nicotine receptors: addiction's smoking gun? 2002. Nat Med, 31:447-9.
18. Niaura R. 2005. Long-term treatment with rimonabant for smoking cessation and the maintenance of abstinence: results from STRATUS-Worldwide trial. Abstract presented at the Society for Research on Nicotine and Tobacco Annual Conference.
19. Silagy C, Lancaster T, Stead L, et al. 2004. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, (3), CD000146.
20. Steinberg MB, Foulds J, Richardson DL, et al. 2006. Pharmacotherapy and smoking cessation at a tobacco dependence clinic. Prev Med, 42:114-9.
21. Tonstad S, Tonnesen P, Hajek P, et al. 2006. Effect of maintenance therapy with varenicline on smoking cessation. JAMA, 296:64-71.
22. US Department of Health and Human Services. 2004. The Consequences of Smoking: A Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
23. VanGaal LF, Rissanen AM, Scheen AJ, et al. 2005. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 365:1389-97.
24. Warner C, Shoaib M. 2005. How does bupropion work as a smoking cessation aid? Addict Biol, 10:219-31.